Patients who may derive particular benefit include: People with type 2 diabetes and hypertension : This combination is extremely common, affecting a substantial proportion of people with type 2 diabetes
Discuss your full medical history with your clinician before starting treatment.
Rapid Risk Reduction Seen in First Months The study found that semaglutide was associated with a 38% reduced risk of major adverse cardiovascular events (MACE) within the first 3 months compared to placebo (36 vs 58, respectively) Within the first 6 months, semaglutide was associated with a 41% reduced risk of MACE compared to placebo (67 vs 113, respectively) Notably, at 3 and 6 months, most patients had not yet lost much weight and many were not yet on the full target dose of semaglutide 2.4 mg weekly
May your vials stay potent, your vendors stay honest, and your protocols stay affordable.
This broader perspective is important because obesity is not just about body weight
Bairds Sandpiper legs are black